Discover CD38 Modulators with Transcreener CD38 Assay Services
The Transcreener CD38 Assay measures the ADPR produced by CD38 (also known as cluster of differentiation 38 or cyclic ADP ribose hydrolase). By measuring the production of CD38 researchers can effectively determine the activity of the enzyme. The assay provides a powerful tool to screen compound libraries for CD38 modulators to help find new therapeutics for a variety of different conditions including autoimmune diseases and cancer.
The assay is currently available as a service performed in-house at BellBrook Labs. Please contact us for questions related to acquiring the assay.
The Role of CD38 as a Therapeutic Target
CD38 is an ectoenzyme found on the surface of a variety of immune cells. It can also be located in other parts of the cell such as the mitochondria. Soluble CD38 is also present in the cytoplasm. As part of the extracellular CD38/CD203a/CD73/CD39 pathway which modulates adenosine production, CD38 is one of the first steps by producing ADPR from NAD+. Extracellular adenosine is a key player in the regulation of inflammation and immunogenicity. As such CD38 provides a potential target for tumor evasion and inflammatory-related disease. Intracellular CD38 is also a target for asthma as cADPR-mediates calcium channels that control smooth muscle associated with breathing.
Detection of ADPR to Measure CD38 Enzymatic Activity
CD38 uses NAD+ to produce the ADPR and cADPR. The assay uses a coupling enzyme that generates AMP from the ADPR produced. The AMP is then measured by the proven Transcreener AMP Assay with an FP readout.